Prelude Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Prelude Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$268K	Buy	+31,640	New	+$302K	0.02%	760
2024 Q2	–	Sell	-44,300	Closed	-$403K	–	1411
2024 Q1	$403K	Buy	+44,300	New	+$314K	0.02%	735
2020 Q4	–	Sell	-200	Closed	-$2K	–	1777
2020 Q3	$2K	Buy	+200	New	+$1.66K	﹤0.01%	1675
2020 Q1	–	Sell	-56,164	Closed	-$222K	–	1861
2019 Q4	$222K	Buy	+56,164	New	+$195K	0.01%	826

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Prelude Capital Management's OCUL Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 31,640 shares worth $268K. The stake represents 0.02% of the portfolio and ranks #760 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in OCUL as recently as Q1 2024.

Prelude Capital Management first reported a position in OCUL in Q4 2019 and has held it in 4 quarters since. The position peaked at $403K in Q1 2024. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Prelude Capital Management held 31,640 shares of Ocular Therapeutix worth $268K as of Q1 2026.
Ocular Therapeutix was a new Prelude Capital Management position in Q1 2026.
Ocular Therapeutix made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #760 holding.
Prelude Capital Management first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 4 quarters since.
Prelude Capital Management's Ocular Therapeutix position peaked at $403K in Q1 2024.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.